Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Limited evidence exists for non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in atrial fibrillation patients post-drug-eluting stent (DES) implantation.
• Current guidelines suggest NOACs, but real-world data on monotherapy efficacy and safety after DES is scarce.

Purpose of the Study:

• To evaluate the noninferiority of NOAC monotherapy compared to combination therapy (NOAC plus clopidogrel) in patients with atrial fibrillation after DES implantation.
• To assess net adverse clinical events (NACE) as a primary endpoint in this patient population.

Main Methods:

• A multicenter, randomized, open-label, noninferiority trial was conducted in South Korea.
• 960 patients with atrial fibrillation and prior DES implantation were randomized 1:1 to NOAC monotherapy or NOAC plus clopidogrel combination therapy.
• The primary endpoint was NACE at 12 months, defined as a composite of death, myocardial infarction, stent thrombosis, stroke, systemic embolism, or major/clinically relevant nonmajor bleeding.

Main Results:

• NOAC monotherapy was noninferior to combination therapy for NACE (9.6% vs. 17.2%), with a significant difference of -7.6 percentage points (P<0.001 for noninferiority).
• A significant superiority of NOAC monotherapy was observed for NACE (hazard ratio, 0.54; P<0.001).
• Major or clinically relevant nonmajor bleeding occurred less frequently in the NOAC monotherapy group (5.2% vs. 13.2%).

Conclusions:

• NOAC monotherapy is a safe and effective alternative to combination therapy in patients with atrial fibrillation who have undergone DES implantation at least one year prior.
• The findings support the use of NOAC monotherapy, potentially simplifying treatment regimens and reducing bleeding risk in this patient cohort.